

PHARMAESSENTIA CORPORATION ANNOUNCES CLOSING OF FOLLOW-ON PUBLIC OFFERING, GENERATING MORE THAN 200M USD TO SUPPORT GROWTH AMBITIONS

October 21, 2022, TAIPEI – PharmaEssentia Corporation (TPEX:6446), a global biopharmaceutical innovator leveraging deep expertise and proven scientific principles to deliver new biologics in hematology and oncology, today announced the closing of a follow-on public offering on the Taipei Exchange of 16,700,000 shares of its stock at a public offering price of TWD 408 per share, generating in total approximately TWD 6.82B (212M USD) to support the company’s continued global expansion and pipeline efforts. All of the shares of common stock were offered by the Company.

“We continue to build a robust global presence with one product now approved in multiple regions and a strong, diversifying pipeline,” said Ko-Chung Lin, PhD, founder and Chief Executive Officer. “This financing as part of our overall growth strategy positions us to pursue critical development efforts and expansion of manufacturing plants to support our ambitions over the next several years.”

Yuanta Securities Corporation acted as the sole underwriter for the offering. Prospectus information has been posted to the Market Observation Post System (twse.com.tw)

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About PharmaEssentia

PharmaEssentia (TPEX: 6446), headquartered in Taipei, Taiwan, is a global and rapidly growing biopharmaceutical innovator. Leveraging deep expertise and proven scientific principles, PharmaEssentia aims to deliver effective new biologics for challenging diseases in the areas of hematology and oncology, with one approved product and a diversifying pipeline. Founded in 2003 by a team of Taiwanese-American executives and renowned scientists from U.S. biotechnology and pharmaceutical companies, today PharmaEssentia is expanding its global presence with operations in the U.S., Japan, China, and Korea, along with a world-class biologics production facility in Taichung, Taiwan.

Forward-Looking Statements

This press release may contain forward-looking statements, including statements regarding our pipeline, research and development efforts, and potential global expansion plans. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995 and similar legislation and regulations under Taiwanese law. These forward-looking statements are based on management

expectations and assumptions as of the date of this press release, and actual results may differ materially from those in these forward-looking statements as a result of various factors. These factors include risks and uncertainties related to the initiation, timing, progress and results of our research and development programs, preclinical studies, clinical trials, regulatory submissions, manufacturing difficulties or delays, commercialization plans, customer and prescriber patterns or practices, and reimbursement activities and outcomes. We do not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof.

Media Contact:

Muriel Huang, muriel_huang@pharmaessentia.com

###